<DOC>
	<DOCNO>NCT00189020</DOCNO>
	<brief_summary>Two ( 2 ) three ( 3 ) instead four vaccination age 6 month pneumococcal conjugate vaccine presume protect child invasive pneumococcal disease like meningitis , least short term till 18-24 month age . The current hypothesis study 2 3 vaccination protect IPD alter pneumococcal nasopharyngeal carriage infant , consequently change pneumococcal transmission induce herd-immunity . Furthermore , antibody development memory may benefit carriage vaccine type S. pneumoniae</brief_summary>
	<brief_title>Effect Two Versus Three Pneumococcal Conjugate Vaccinations</brief_title>
	<detailed_description>Two ( 2 4 month ) three vaccination ( 2,4 11 month ) 7-valent pneumococcal conjugate vaccine Prevnar infant presume provide 90 % protection invasive pneumococcal disease ( IPD ) vaccine type pneumococcus , least 18-24 month age . Licensure vaccine however base study 3 vaccination 6 month booster vaccination half year later ( 3+1 scheme ) . Cost-effectiveness national infant vaccination program ( NIPs ) much improve high herd-immunity effect , observe USA licensure Prevnar 2000 , IPD AOM . However , overall pneumococcal carriage reduction ( nasopharyngeal replacement ) assess study reduce dos . With reduced carriage reduction , effect respiratory tract infection herd immunity may significantly less . The primary aim current study compare effect 2-doses ( age 2 4 month ) 3-doses scheme ( 2+1 , 2 , 4 11 month ) nasopharyngeal pneumococcal carriage replacement family transmission ( sibs caregiver ) , order allow model herd-immunity . The secondary aim determine effect reduce dos scheme serum antipneumococcal antibody level age 12 24 month . A third aim determine antipneumococcal antibody level memory B-cell development booster vaccination 24 month age , 2 2+1 dos compare first vaccination 24 month age . Opportunities determination nasopharyngeal colonize pneumococcus unvaccinated infant Netherlands implementation Prevnar NIP , evaluation replace pneumococci nasopharynx vaccination analysis effect colonize bacteria like H.influenzae , M. catarrhalis S.aureus . Furthermore , relation colonize pneumococci serotypes cause IPD Netherlands evaluate . Methods : 1000 infant family include randomize , control study 3 intervention group 1 . Prevnar 2 4 month 2 . Prevnar 2 , 4 11 month 3 . Prevnar 24 month ( control ) The child follow 2 year age nasopharyngeal swabs bacterial culture first vaccination , 6 , 12 , 18 24 month age . One sibling one parent/caregiver swab infant 12 24 month . Blood antibody determination obtain 80 child group 1 2 , 30 child control group . Questionnaires health respiratory infection antibiotic prescription RTI obtain . At 24 month age , child group 1 2 offer booster vaccination . Antibody level measure 4 week vaccination 2 year age subset 80 child per group compare 80 child receive first vaccination 24 month age .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Newborn infant eligible participation national infant vaccination program Netherlands exclusion national vaccination program presence medical condition require treatment interfere effect vaccination know suspected allergy component pneumococcal conjugate vaccine know suspected immunodeficiency disease previous treatment plasma immunoglobulins previous vaccination hepatitis B vaccination coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>pneumococcal conjugate vaccination</keyword>
	<keyword>nasopharyngeal carriage</keyword>
	<keyword>herd immunity</keyword>
	<keyword>antipneumococcal antibody</keyword>
	<keyword>respiratory tract infection</keyword>
	<keyword>National infant vaccination program</keyword>
</DOC>